Clinical Trial

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-09-27; most recent amendment 2024-11-19.
Status change: Not Yet Recruiting → Recruiting 2021-06-15
Trial Details
NCT Number NCT04110301
Lead Sponsor Beijing Mabworks Biotech Co., Ltd.
Conditions Follicular Lymphoma and Marginal Zone Lymphoma
Enrollment 53 participants
Start Date 2019-11-28
Primary Completion 2024-01-09 (estimated)
Study Completion 2025-05 (estimated)
Updated on ClinicalTrials.gov 2024-11-20